TickerFacts.

Volitionrx Ltd (VNRX): Shareholders' Equity

Annual figures by period end, from SEC filings.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2022-12-31 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

-$34.25M
As of 2025-12-31
-$32.16M
As of 2026-06-30
$21.18M2011-12-31: $1.09M2012-12-31: $833.8K2013-12-31: $680.7K2014-12-31: $368.2K2015-12-31: $6.04M2016-12-31: $21.18M2017-12-31: $9.96M2018-12-31: $12.14M2019-12-31: $14.20M2020-12-31: $16.29M2021-12-31: $17.72M2022-12-31: -$2.57M2023-12-31: -$7.80M2024-12-31: -$24.91M2025-12-31: -$34.25M-$34.25M
2011-12-31 Shareholders' Equity (USD) 2025-12-31
Period endedShareholders' EquityChange YoYSource filing
2025-12-31-$34.25Mn/m2026-03-31, Balance as of period end
2024-12-31-$24.91Mn/m2026-03-31, Balance as of period end
2023-12-31-$7.80Mn/m2025-03-31, Balance as of period end
2022-12-31-$2.57Mn/c2024-03-25, Balance as of period end
2021-12-31$17.72M+8.8%2023-03-15, Balance as of period end
2020-12-31$16.29M+14.8%2022-03-30, Balance as of period end
2019-12-31$14.20M+17.0%2021-03-22, Balance as of period end
2018-12-31$12.14M+21.9%2020-02-20, Balance as of period end
2017-12-31$9.96M-53.0%2019-03-13, Balance as of period end
2016-12-31$21.18M+250.3%2018-03-01, Balance as of period end
2015-12-31$6.04Mn/m2017-03-10, Balance as of period end
2014-12-31$368.2K-45.9%2016-03-11, Balance as of period end
2013-12-31$680.7K-18.4%2015-03-18, Balance as of period end
2012-12-31$833.8K-23.4%2014-03-28, Balance as of period end
2011-12-31$1.09Mn/a2014-03-28, Balance as of period end

Shareholders' Equity at similar companies

Companies with the same SEC industry code (In Vitro & In Vivo Diagnostic Substances), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedShareholders' EquityChange YoY
Volitionrx Ltd (VNRX)2025-12-31-$34.25Mn/m
Celldex Therapeutics, Inc. (CLDX)2025-12-31$527.16M-29.4%
Insight Molecular Diagnostics Inc. (IMDX)2025-12-31-$31.46Mn/m
Biomerica Inc (BMRA)2026-05-31$2.63M-35.9%
Anbio Biotechnology (NNNN)2025-12-31$30.16M+75.4%
Aspira Women's Health Inc. (AWHL)2025-12-31-$6.93Mn/m
Immucell Corp (ICCC)2025-12-31$27.06M-1.7%
Alpha Teknova, Inc. (TKNO)2025-12-31$68.78M-16.5%
Intellia Therapeutics, Inc. (NTLA)2025-12-31$671.39M-23.0%

Compare VNRX, CLDX, IMDX, BMRA side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗